Halozyme Therapeutics Inc (HALO)
38.03
-0.36
(-0.94%)
USD |
NASDAQ |
Apr 17, 16:00
38.03
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Cash from Operations (Quarterly): 102.35M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 102.35M |
September 30, 2023 | 132.41M |
June 30, 2023 | 66.84M |
March 31, 2023 | 86.96M |
December 31, 2022 | 82.45M |
September 30, 2022 | 69.64M |
June 30, 2022 | 40.22M |
March 31, 2022 | 47.80M |
December 31, 2021 | 82.52M |
September 30, 2021 | 121.74M |
June 30, 2021 | 36.89M |
March 31, 2021 | 58.30M |
December 31, 2020 | 50.92M |
September 30, 2020 | 6.084M |
June 30, 2020 | 3.294M |
March 31, 2020 | -4.844M |
December 31, 2019 | -26.62M |
September 30, 2019 | -29.59M |
June 30, 2019 | -24.79M |
March 31, 2019 | -4.424M |
December 31, 2018 | 10.46M |
September 30, 2018 | -18.93M |
June 30, 2018 | -18.86M |
March 31, 2018 | -22.18M |
December 31, 2017 | 153.25M |
Date | Value |
---|---|
September 30, 2017 | 20.26M |
June 30, 2017 | -17.00M |
March 31, 2017 | -22.46M |
December 31, 2016 | -15.77M |
September 30, 2016 | -8.748M |
June 30, 2016 | -12.84M |
March 31, 2016 | -13.02M |
December 31, 2015 | -15.20M |
September 30, 2015 | -16.98M |
June 30, 2015 | 8.938M |
March 31, 2015 | -13.84M |
December 31, 2014 | -0.939M |
September 30, 2014 | -13.18M |
June 30, 2014 | -15.77M |
March 31, 2014 | -17.63M |
December 31, 2013 | -15.22M |
September 30, 2013 | -12.41M |
June 30, 2013 | -10.96M |
March 31, 2013 | -10.75M |
December 31, 2012 | -16.87M |
September 30, 2012 | -14.30M |
June 30, 2012 | -13.76M |
March 31, 2012 | -19.36M |
December 31, 2011 | -13.50M |
September 30, 2011 | -13.44M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-29.59M
Minimum
Sep 2019
132.41M
Maximum
Sep 2023
47.50M
Average
50.92M
Median
Dec 2020
Cash from Operations (Quarterly) Benchmarks
Johnson & Johnson | 7.863B |
Globus Medical Inc | 104.67M |
Denali Therapeutics Inc | -98.66M |
AIM ImmunoTech Inc | -9.758M |
Protalix BioTherapeutics Inc | 3.595M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | -8.291M |
Cash from Financing (Quarterly) | -249.92M |
Free Cash Flow | 373.28M |
Free Cash Flow Per Share (Quarterly) | 0.761 |
Free Cash Flow to Equity (Quarterly) | 98.13M |
Free Cash Flow to Firm (Quarterly) | 104.16M |
Free Cash Flow Yield | 7.32% |